Jin Medical International Ltd. (ZJYL) Stock Analysis

Price updated 4 days ago · SEC data refreshed 3 months ago ⓘ · Not investment advice

Jin Medical International Ltd.

ZJYL Healthcare Medical Devices📄 SEC filings ↗
Valuation N/A
Long-term trend (200d) 62% below 200-day Risk 40/100 Elevated
▾ What's in the 40/100 risk score? (higher = riskier)
Fundamental health (43%) 51/100 → +21.9
leverage 20/100 · FCF trend 90/100 · Altman Z not scored — input unavailable (see Financial Health)
Smart money (short interest + insider buying) (31%) 31/100 → +9.7
Macro backdrop (VIX, curve, credit, fear/greed + week-over-week momentum) (26%) 33/100 → +8.5
Total40/100

Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). It excludes the Altman Z score, whose retained-earnings input this filer does not report separately. See the Financial Health section for the full balance-sheet read.

💵 Price $2.07 · 4 days ago 📄 Financials SEC EDGAR · refreshed 3 months ago
📍 START HERE

How to read ZJYL

We are not publishing an intrinsic value for this one — the section below says exactly why. Everything on this page that comes straight from the filings and the tape is still here; treat the missing valuation as a known gap, not as a verdict on the business.

Where to start — the sections that matter most for this stock
  1. 1 Reported earnings & margins ↓
    What the company actually reported — unaffected by the valuation being held.
  2. 2 Balance sheet & book value ↓
    Assets, liabilities and equity as filed.
  3. 3 Who's selling & betting against it ↓
    Insider and short-interest behaviour needs no valuation model.
Or — what are you trying to decide?
A note on process: fear-driven decisions — including fear of missing out — tend to be the expensive ones. A stock up 10% a day for three days is excitement, not evidence. Whichever reader you are, the data below is there to be checked before anything is decided.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ The price sits far above our cash-flow model

Our DCF for ZJYL lands well below today's price. For a non-cyclical that usually means the market is pricing in growth far beyond recent cash flows (or there's a data quirk), so we don't headline a single fair-value number.

What to use instead: The Reverse-DCF shows exactly how much growth the price demands — decide whether that's realistic. Pair it with peer multiples.

This note is only about the single DCF fair-value number — ZJYL's full financial statements, health scores, and written analysis are all below.

ⓘ Why does ZJYL trade at $2.07?

Jin Medical International Ltd. has 156.5 million shares outstanding. At $2.07 per share, the market values all outstanding ZJYL equity at $324 million. That's market capitalization, not enterprise value — enterprise value also accounts for debt and cash (ZJYL carries little or no debt, so the two are close here). The share price by itself tells you almost nothing — a company can pick any share price by splitting or issuing more shares. What matters is the total value (Market Cap?Market Cap — The total dollar value the market is assigning to the entire company.
Why it matters: This is the number that actually matters when comparing companies. Two companies with the same business but different share counts have the same market cap.
Reference: Mega cap >$200B · Large $10–200B · Mid $2–10B · Small $300M–2B · Micro <$300M
Full explanation →) compared to what the business actually produces. This page values ZJYL in Per Share?Per Share — A company-level figure divided by total shares — what one share represents.
Why it matters: Per-share metrics are the only way to fairly compare two companies with different share counts.
Full explanation → economics — what each share represents of the underlying business. Play with the share-price calculator on the homepage →

Loading insider & short-seller data…
Checking filings for failure warnings…
PEER BASKET — LIMITED COMPARABLES

⚠ We found only 2 genuine same-industry (Medical Devices) comparables — fewer than the 4 we require for a reliable median. The 8 names in the table below therefore include 6 broader Healthcare names marked fallback, whose business models and margins differ — which is why any median below is computed over that wider set, not over true comparables. So we do not derive a peer-implied share value here. Read the multiples as rough context only.

How does ZJYL stack up against its closest peers?

Ideally we compare ZJYL only to same-industry peers, but too few exist in our universe right now, so the basket below mixes in broader-sector names. Treat the multiples as rough context, not a valuation. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.

▾ What's "EV / Sales" in plain English?

EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.

EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).

p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.

What peers trade at (p25 / median / p75)
EV / Sales?EV / Sales — For every $1 of yearly revenue, this is how many dollars investors pay to own the whole business (including debt).
Why it matters: Works for pre-profit growth companies where P/E and FCF don't apply. The most apples-to-apples cross-company multiple because it ignores accounting choices.
Reference: 1–3x for mature companies · 4–10x for software/SaaS · 10–20x for hypergrowth · >20x is rare and demanding
Full explanation →		 1.3x / 4.7x / 7.4x
EV / Gross Profit?EV / Gross Profit — Enterprise value divided by gross profit — the multiple paid for what each dollar of sales contributes after direct costs.
Why it matters: More refined than EV/Sales for high-margin businesses (software, marketplaces) where gross margin is the real economic engine.
Reference: 8–15x for SaaS · 15–25x for hypergrowth software · >30x demanding
Full explanation →		 1.6x / 6.1x / 9.6x

Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 peers (broad — see caveat); implausible multiples excluded.

Peer-implied value check
We're not showing a peer-implied price for ZJYL: with only 2 genuine same-industry comparables, a median built partly from broader-sector names would be misleading. Lean on the DCF above; use the multiples table only as loose context.

⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.

▾ View peer list (8)
Ticker Company Industry Mcap EV/Sales EV/GPEV/EBIT FCF Yield
OSUR ORASURE TECHNOLOGIES INC Medical Devices $296M 2.6x 6.1x— 2.1%
OBIO Orchestra BioMed Holdings, Inc. Medical Devices $234M 7.4x —— 1.1%
SI SHOULDER INNOVATIONS, INC. Medical Devices ·fallback $305M 6.8x 8.8x— 32.7%
OFIX Orthofix Medical Inc. Medical Devices ·fallback $375M 0.6x 0.9x— 62.1%
SGHT Sight Sciences, Inc. Medical Devices ·fallback $264M 4.0x 4.6x— 1.3%
PROF Profound Medical Corp. Medical Devices ·fallback $247M 15.7x 22.1x— 0.7%
TMCI TREACE MEDICAL CONCEPTS, INC. Medical Devices ·fallback $224M 1.3x 1.6x— 9.1%
UTMD UTAH MEDICAL PRODUCTS INC Medical Devices ·fallback $212M 5.5x 9.6x18.6x 6.5%
FINANCIAL HEALTH SCREENS

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
n/a
Not reliably computable

We can't produce a trustworthy Altman Z here: retained earnings weren't separately reported in our data, so a core input would have to be fabricated. Rather than show a categorical "distress" verdict from an invented number, we mark it unavailable. Judge financial health from the leverage, cash position, and the measurable Piotroski checks instead.

Piotroski F-Score?Piotroski F-Score — A 9-point quality checklist scoring profitability, leverage, and operating efficiency.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
5 / 9
Mediocre
▾ The checks — what passed, what didn't (and what we couldn't measure)
  • ✓ Positive net income
    Net income $1.2M in FY2025.
  • ✓ Positive operating cash flow
    Operating cash flow $2.9M (was -$1.2M the prior year).
  • ✓ Cash flow backs up reported profit
    Operating cash flow $2.9M vs net income $1.2M.
  • ✗ Return on assets improving
    Return on assets 2.2% vs 8.0% a year ago.
    Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
  • ✓ Debt load (vs assets)
    The filing reports no interest-bearing debt in either year (total assets $53.4M).
  • ✗ Short-term liquidity (current ratio)
    Current ratio 1.86x vs 2.50x a year ago.
    Why this matters: The current ratio compares assets it can turn to cash within a year against bills due within a year. Below 1.0 means it may struggle to cover near-term obligations.
  • ✓ Share count (dilution)
    Share count held roughly flat (156.5M → 156.5M year-over-year).
  • ✗ Pricing power (gross margin)
    Gross margin 29.2% vs 40.4% a year ago.
    Why this matters: Rising gross margin means stronger pricing power or lower input costs — a sign of competitive strength. Falling margin signals pressure.
  • ✗ Sales per asset (asset turnover)
    Asset turnover 0.39x vs 0.51x a year ago.
    Why this matters: Asset turnover measures how much revenue each dollar of assets generates. Rising = more productive use of the asset base.

Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.

INTERACTIVE — TWEAK YOUR ASSUMPTIONS

What if you assume different inputs?

Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount Rate?Discount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 10.0%, the figure our model used for ZJYL. Open Advanced to also change beta, growth and the rate path.

Note: no headline intrinsic value is published for this stock (the valuation is held for a data-quality reason — see the notes above). The calculator below is a what-if tool: the values it produces are your assumptions played out, not our estimate.

4.5% (risk-free)9-10% normal18% (deep-risk)
0%2-3% (GDP)5% (rarely sustainable)

A full intrinsic value isn't shown for ZJYL because the valuation is currently held for a data-quality reason (see the guardrail notes above). The reverse-DCF reading still works — it needs only the price and cash flow — but we won't publish a forward value until the underlying data passes our checks.

For comparison — the revenue growth today's price already assumes
—
—

—

⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
Where the discount rate comes from — discount rate = risk-free + beta × equity-risk-premium
What you'd earn risk-free from government bonds — the floor under every other rate. Slide it down to model the market expecting rate cuts (value rises); up for higher-for-longer.
The extra yearly return investors demand for owning stocks instead of safe bonds — the price of risk. History runs ~4.5–6.5%; we default to 5.5% (slightly conservative). It's an estimate, not a law — lower it if you think equities are less risky than that.
Inflation reduces the purchasing power of a nominal return: a 9% gain at 3% inflation is about 6% in real terms. The intrinsic value above is already in today's dollars (a nominal DCF carries inflation in both the growth and the discount rate), so this switch does not change the value — it restates the return in real terms.
Higher beta → higher discount rate (sets the rate above). 1.0 = moves with the market.
What you think ZJYL can grow revenue for ~5 years, then fades to terminal.
For a pre-profit company: the % of revenue that eventually becomes free cash flow once mature. (Our published value uses the sector norm.)
All inputs start at the values our model used.

    Copy shareable link to this scenario →

    Price$2.07
    Model IVNot applicable — DCF couldn't price this stock. The other valuation lenses on this page (reverse-DCF, peers, sector lens — whichever apply to this filer) carry the read instead.

    A standard discounted cash flow?DCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
    Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
    Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
    Full explanation →     (DCF) valuation is not meaningful for Jin Medical International Ltd. because the model implies no positive equity value under its assumptions, largely due to roughly flat revenue and compressing gross margins. Investors are likely focused on the company's consistent profitability and positive operating cash flow, betting on a potential re-acceleration of revenue growth in its medical device segments. The number one quantifiable risk is the persistent revenue stagnation at -0.1% per year over the last four years.

    ⚠️ Revenue declining

    As of 3 months ago

    ANATOMY

    Anatomy of a share

    What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

    ZJYL Jin Medical International Ltd. stock anatomy showing per-share revenue, operating expenses, free cash flow, and debt
    5.8%
    profit
    Where each $1 of revenue goes
    Net profit — 5.8¢ of every dollar ($0.01/sh = latest fiscal-year net income ÷ current shares. The table below shows GAAP diluted EPS of $0.01, computed on that year's weighted-average diluted shares — the share count moved, which is why they differ)
    Costs & taxes — 94.2¢ (on $0.13 revenue/sh)
    Net margin = net income ÷ revenue (most recent fiscal year).
    Plain English: each share (at $2) represents $0.13 of revenue per share per year, $0.01 of net income per current share, and $0.02 of cash burned per share (negative free cash flow) from the latest fiscal year. The filing reports no interest-bearing debt — the 23.8M of total liabilities on the balance sheet are operating items (payables, leases, deferred taxes), not borrowings.
    What's free cash flow / what do these mean?

    Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.

    Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.

    Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.

    Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.

    THE KEY DEBATE

    What you actually need to decide

    Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

    🐂 The Bull Case
    Revenue must re-accelerate from the current -0.1%/yr decline, potentially driven by new product launches or market expansion, to justify a higher valuation.
    🐻 The Bear Case
    The compressing gross margin (30.6% to 29.2%) combined with flat revenue suggests increasing competitive pressure or rising costs, which could erode future profitability if not reversed.
    📌 Signposts to watch — update your view as these print
    • Quarterly revenue growth above 0%
    • Stabilization or expansion of gross margins
    • Announcements of new product lines or market entries
    MOMENTUM — WHAT'S GETTING BETTER & WORSE

    The trend, in plain numbers (FY2024 → FY2025, latest reported)

    Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.

    ⚠ Worsening
    • Revenue fell -12% to $20.7M.
    • Free cash flow is negative at -$3.7M — the cash burn widened vs last year.
    • Gross margin shrank to 29% (-11 pts).
    • Net income fell -68% to $1.2M.

    Nothing was clearly improving year-over-year.

    WHO

    Management & Leadership

    Jin Medical International Ltd. is led by its founder and CEO, Mr. Erdong Chen, who has been instrumental in guiding the company's strategic direction and operations since its inception. The company focuses on the medical device sector, particularly in rehabilitation and elderly care products.

    Erdong Chen
    Chief Executive Officer
    WHAT

    What They Make

    Jin Medical International Ltd. designs, develops, manufactures, and sells a range of medical devices, primarily focusing on rehabilitation and elderly care products, which are purchased by healthcare providers and individual consumers.

    End Markets

    Rehabilitation centersElderly care facilitiesIndividual consumers

    Revenue Drivers

    Wheelchairs and mobility aids
    Medical beds and furniture
    Other rehabilitation equipment
    Market Cap: 324.1MBeta: 1.31
    WHY

    Why Is It Priced Like This?

    Why Customers Pay

    Improved mobility and independence for users
    Enhanced comfort and safety for patients
    Cost-effective solutions for healthcare providers
    No discounted-cash-flow value for this filer This company's reported free cash flow is negative, so a discounted-cash-flow valuation has no positive cash stream to discount. That is a fact about the business, not missing data — the reported figures below are complete.

    What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.

    The market is likely pricing Jin Medical International based on its consistent profitability (net income positive 5/5 years) and positive operating cash flow (positive 4/5 years), despite flat revenue. The market may be assigning value to potential future market expansion or new product introductions in the growing elderly care sector, which are not captured in the backward-looking cash flow model.

    HOW

    Business Model & Valuation

    How They Make Money

    Sales of wheelchairs and mobility devices
    Sales of medical beds and related furniture
    Sales of other rehabilitation and assistive devices

    The company has funded itself through its positive operating cash flow, as indicated by positive operating cash flow in 4 out of 5 years, and has not indicated significant dividends or buybacks.

    Growth / Revenue DCF

    Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.

    Show advanced inputs
    Revenue Growth2.0%

    What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

    WHEN

    Maturity & Competitive Position

    Growth / re-investment phase

    Moat Signals

    Established product portfolio
    Distribution network
    Brand recognition in specific niches

    Revenue has been roughly flat at -0.1% per year over the last four years, while net income has been positive for 5 out of 5 years.

    WHERE

    Geography & Markets

    Jin Medical International Ltd. operates primarily in the medical device sector, with its main operations likely concentrated in Asia, given its company profile, though specific geographic revenue mix percentages are not available from current data sources.

    Geographic Risks

    Geographic concentration risk in its primary markets, making it vulnerable to regional economic downturns or regulatory changes.
    Intense competition within the medical device industry, particularly in the rehabilitation and elderly care segments.
    SIGNALS

    Market Signals

    These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

    Model neutral, tape neutral - aligned.
    RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
    Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
    Reference: 30–70 normal · >70 overbought · <30 oversold
    Full explanation →     (14)    48.2NeutralMomentum is balanced — neither overbought nor oversold.
    MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
    Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
    Reference: Line above signal = bullish momentum · below = bearish
    Full explanation →    BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
    50-Day Average$2.17Price below (-4.6%)Price below its 50-day average = near-term downtrend.
    200-Day Average$5.41Price belowThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
    50 vs 200 CrossDeath50-day below 200-dayA "death cross" — the medium trend is below the long trend (often read as bearish).

    Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

    NEWS

    What's been happening

    Jin Medical International Ltd. operates in the medical device industry, primarily focusing on manufacturing and selling wheelchairs and living aids. Over the past six months, the company has reported financial results indicating continued operations in its core segments. There haven't been significant announcements regarding new product launches or major regulatory actions. The company's operational focus appears to remain on its existing product lines and market presence within the medical equipment sector.

    Aggregate sentiment: neutral (0.00)
    • routine financial reporting
    • Nasdaq compliance issue
    Jin Medical International Ltd. Announces Unaudited Financial Results for the Six Months Ended March 31, 2023 wire · 2023-11-20

    Jin Medical International Ltd. reported its unaudited financial results, providing an update on its revenue and operational performance for the first half of its fiscal year. The report detailed the company's financial standing and ongoing business activities in its medical device segments.

    Source →
    Jin Medical International Ltd. Files Annual Report on Form 20-F SEC Filing · 2024-01-29

    The company filed its annual report with the SEC, providing a comprehensive overview of its business, financial condition, and operational results for the fiscal year ended September 30, 2023. This filing offers detailed insights into the company's performance and strategic direction.

    Source →
    Jin Medical International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency wire · 2024-03-15

    Jin Medical International Ltd. received a notification from Nasdaq indicating that it was not in compliance with the minimum bid price requirement. This notice typically triggers a compliance period for the company to regain adherence to the listing standard.

    Source →

    News summary written by Gemini gemini-2.5-flash, refreshed Sep 10, 2026. AI can be wrong; verify before acting.

    QUALITY

    Data Quality & Risk Flags (7 notes — click to expand/collapse)
    HIGH Revenue declining
    Guardrail Notes (6)
    • FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
    • Terminal growth (3%) capped to 1.6% (80% of near-term growth 2%).
    • Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
    • Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
    • Extreme valuation: price is far above the model output ($0.06) and this is not a cyclical — output likely dominated by a data issue. Suppressed.
    • DATA UNAVAILABLE: per-share values suppressed due to missing/unreliable shares data.
    FINANCIALS

    Financial Statements (5-year tables — click to expand)

    From Jin Medical International Ltd.'s SEC filings (EDGAR).

    Income (5yr)

    YearRevenueNet IncomeEPS
    202520.7M1.2M$0.01
    202423.5M3.7M$0.02
    202319.8M2.9M$0.02
    202219.2M2.7M$0.02
    202120.8M2.6M$0.02

    Cash Flow (5yr)

    YearOperating CFCapEx− SBC & adj.Free Cash Flow
    2025 2.9M 6.6M — -3.7M
    2024 -1.2M 144,949 — -1.4M
    2023 3.1M 113,937 — 3.0M
    2022 1.6M 40,166 — 1.5M
    2021 5.8M 42,881 — 5.8M

    How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.

    Balance Sheet

    Total Assets53.4M
    Total Liabilities23.8M
    Equity29.6M
    VIDEOS

    Recent video coverage

    Top recent YouTube videos by date. We don't endorse the channels — these are surfaced for context.

    YOU MIGHT ALSO LIKE

    Similar companies worth a look

    Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

    PG
    Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
    ⚠️ Not investment advice. Automated model outputs, last refreshed May 31, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
    ← Browse Stocks See sector peers →
    🔔 Follow $ZJYL — free insider alerts
    One email when an insider buys $ZJYL on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.